Anthos Takes On Pharma Giants In Factor XI Anticoagulation Space
Start-Up Was First To Start A Phase III Trial
CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.
You may also be interested in...
Bristol and Janssen reported Phase II data at the ESC Congress in secondary stroke prevention, an indication not covered by Factor Xa inhibitors. BMS unveiled a three-indication Phase III program.
With Nubeqa establishing itself as a strong option for prostate cancer, Bayer is shifting its short-term focus from oncology onto cardiovascular and plotting a late-stage plan for asundexian, its follow-up to Xarelto.
The US pharma giant is planning ahead for Keytruda’s swansong, and hopes that wave of new cardiovascular drugs can help maintain its growth into the next decade.